BLCO

Bausch + Lomb is rated a buy, driven by a robust pipeline, revenue growth, and a recent return to profitability. All three business segments posted Q3 revenue growth, with total revenue up 7% year-over-year and operating cash flow surging. BLCO's valuation appears fair, reflecting its below-investment-grade status and elevated leverage risk, but upward earnings revisions signal potential catalysts.

Does Bausch + Lomb (BLCO) have what it takes to be a top stock pick for momentum investors? Let's find out.

REPYY, BLCO, BOOM, ULH and MEOH stand out as relative price strength picks amid a post-midterm rally, backed by solid fundamentals and upbeat earnings estimates.

BLCO, VLO, and HAS it to the Zacks Rank #1 (Strong Buy) growth stocks list on November 5, 2026.

Bausch + Lomb (BLCO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Investors interested in Medical Services stocks are likely familiar with Bausch + Lomb (BLCO) and HealthEquity (HQY). But which of these two stocks is more attractive to value investors?

ENTG, CNXN and BLCO made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 2, 2026.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

YPF, PBR, BLCO, LFUS and VRT have been added to the Zacks Rank #1 (Strong Buy) List on November 2, 2026.